A comparison of the cellular electrophysiology of mexiletine and sotalol, singly and combined, in canine Purkinje fibers.

Abstract:

:To determine if combinations of mexiletine and sotalol retain Class I and III electrophysiologic actions, using standard microelectrode techniques, we examined the electrophysiologic effects on canine Purkinje fibers of solutions of mexiletine (3.1-100 microM), sotalol (3.1-400 microM), and combinations of the two drugs, at stimulation frequencies of 1.5 and 2.0 Hz. The combinations consisted of 12.5 microM of one drug combined with 3.1, 12.5, and 50 microM of the other. Mexiletine caused a concentration dependent depression of Vmax, the degree of depression always being greater at the more rapid frequency. At concentrations above 50 microM, sotalol depressed Vmax slightly. Increasing the stimulation frequency did not result in further Vmax depression. The addition of sotalol did not alter the Vmax depression produced by mexiletine but prior exposure to sotalol attenuated the effect of subsequent mexiletine. Both drugs reduced action potential amplitude and in combination their effects on this parameter were additive. Sotalol prolonged and mexiletine shortened action potential duration. Low concentrations of mexiletine reversed the prolongation caused by sotalol, whereas the addition of sotalol did not alter the effect of mexiletine. Mexiletine shortened the effective refractory period at low concentrations and prolonged it at high concentrations. Sotalol prolonged the effective refractory period at all concentrations. Exposure to a low concentration of sotalol did not alter the effects on the effective refractory period of subsequent exposure to mexiletine but a low concentration of mexiletine reduced the prolongation from subsequent sotalol. Thus, the combination of mexiletine and sotalol may add a Class II action to the Class I effects of mexiletine but the mexiletine prevents the Class III effects of sotalol.

journal_name

J Cardiovasc Pharmacol

authors

Berman ND,Loukides JE

doi

10.1097/00005344-198809000-00005

subject

Has Abstract

pub_date

1988-09-01 00:00:00

pages

286-92

issue

3

eissn

0160-2446

issn

1533-4023

journal_volume

12

pub_type

杂志文章
  • Vasodilatory effect of ghrelin, an endogenous peptide from the stomach.

    abstract::Ghrelin is a novel growth hormone (GH)-releasing peptide, isolated from the stomach, which is identified as an endogenous ligand for GH secretagogues receptor. Although both ghrelin and its specific receptor are expressed in blood vessels, the cardiovascular effects of ghrelin remain unknown. To clarify whether ghreli...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200206000-00001

    authors: Okumura H,Nagaya N,Enomoto M,Nakagawa E,Oya H,Kangawa K

    更新日期:2002-06-01 00:00:00

  • Candesartan prevents myocardial fibrosis during progression of congestive heart failure.

    abstract:BACKGROUND:The goal of this study was to determine whether an Angiotensin II receptor antagonist, candesartan, prevents myocardial fibrosis more effectively than enalapril in animals with a non-ACE pathway during the progression of congestive heart failure (CHF). METHODS AND RESULTS:Dogs were randomly assigned to one ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200406000-00016

    authors: Onishi K,Dohi K,Koji T,Funabiki K,Kitamura T,Imanaka-Yoshida K,Ito M,Nobori T,Nakano T

    更新日期:2004-06-01 00:00:00

  • Effects of antihypertensive drugs on atherogenic factors: possible importance of drug selection in prevention of atherosclerosis.

    abstract::The treatment of hypertension is clearly beneficial. Blood pressure reduction with antihypertensive drugs reduces mortality and the incidence of complications such as stroke, renal failure, and congestive failure. However, analysis of long-term studies using different antihypertensive drugs indicates that the outcome ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Spence JD

    更新日期:1985-01-01 00:00:00

  • Emerging pathophysiological concepts in hypertension.

    abstract::Essential hypertension is now considered a disease of pressure regulation implicating a multiplicity of physiological mechanisms. It is probably genetically predisposed and is associated with altered sensitivity to the sodium ion and a more than chance association with other clinical diseases. New concepts are emergin...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Frohlich ED

    更新日期:1984-01-01 00:00:00

  • Treatment of heart failure: state of the art and prospectives.

    abstract::Heart failure is unique among the major cardiovascular disorders in that it alone is increasing in prevalence while there has been a striking decrease in other conditions. Some of this can be attributed to the aging of the U.S. and European populations. The ability to salvage patients with myocardial damage is also a ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200111002-00015

    authors: Greenberg B

    更新日期:2001-11-01 00:00:00

  • Functional bases for individualities among vascular smooth muscles.

    abstract::This review deals with cellular factors that contribute to individualities of vascular smooth-muscle function in different organ systems and at different levels of the vascular tree. Particular attention has been given to: membrane receptors responsive to catecholamines, serotonin, angiotensin II, dopamine, and acetyl...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00005344-198500073-00001

    authors: Bell DR,Webb RC,Bohr DF

    更新日期:1985-01-01 00:00:00

  • Attenuation of experimental subarachnoid hemorrhage-induced cerebral vasospasm by CGS 26303, an endothelin-converting enzyme inhibitor.

    abstract::The effect of CGS 26303, an endothelin-converting enzyme inhibitor, on the prevention and reversal of cerebral vasospasm was investigated in a rabbit model of subarachnoid hemorrhage (SAH). In the prevention study, rabbits were injected with 3 ml of autologous blood in the cisterna magna and treatment with CGS 26303 i...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199800001-00089

    authors: Kwan AL,Bavbek M,Jeng AY,Toyoda T,Kassell NF,Lee KS

    更新日期:1998-01-01 00:00:00

  • Alpha-adrenoceptor blockade in patients with mild to moderate hypertension: long-term renal effects of doxazosin.

    abstract::Using constant infusion technique and a water-loading procedure, we investigated renal hemodynamic and excretional variables in 15 essential hypertensive patients [diastolic blood pressure (DBP) 102 +/- 10 mm Hg] after 3 weeks of placebo and after 16 weeks of treatment with a postjunctional alpha 1-adrenoceptor-antago...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00005344-199209000-00015

    authors: Krusell LR,Christensen CK,Pedersen OL

    更新日期:1992-09-01 00:00:00

  • Acetylcholinesterase inhibitor (donepezil hydrochloride) reduces heart rate variability.

    abstract::An acetylcholinesterase inhibitor (donepezil hydrochloride) has recently been used for the treatment of senile dementia of Alzheimer type. The effect of this acetylcholinesterase inhibitor on the autonomic nervous control of the heart was investigated in 17 patients with senile dementia of Alzheimer type. Donepezil ad...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Masuda Y,Kawamura A

    更新日期:2003-01-01 00:00:00

  • Extracellular ATP increases [Ca2+]i in primarily cultured pig coronary smooth muscle cells via a P2Y purinoceptor subtype.

    abstract::In primarily cultured pig coronary smooth muscle cells, extracellular adenosine triphosphate (ATP; 10(-9) to 10(-3) M) dose-dependently increases intracellular calcium ([Ca2+]i). The [Ca2+]i transients measured by fura-2 fluorescence consist of peak and plateau phases with [Ca2+]i values of 191.84 +/- 5.67 nM (n = 10)...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199905000-00019

    authors: Seiler L,Matyas S,Fleckenstein-Grün G

    更新日期:1999-05-01 00:00:00

  • Age-dependent changes in the beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in human right atrium.

    abstract::With increasing age, cardiac beta-adrenoceptor function decreases. To study possible mechanisms underlying this process, we assessed in right atrial appendages from 52 patients of different ages (group A, < 20 years, mean age 3.7 +/- 1.0 years, n = 20; group B, 20-50 years, mean age, 37.9 +/- 2.3 years, n = 9; group C...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00005344-199507000-00004

    authors: Brodde OE,Zerkowski HR,Schranz D,Broede-Sitz A,Michel-Reher M,Schäfer-Beisenbusch E,Piotrowski JA,Oelert H

    更新日期:1995-07-01 00:00:00

  • Role of the endothelium and cyclic GMP in renal vasodilator responses to cryptolepine in rats.

    abstract::Isolated perfused rat kidney was used to examine the possible mechanisms involved in the hypotensive/vasodilator actions of cryptolepine. In kidneys preconstricted by phenylephrine (PE 5-7.5 x 10(-7) M), cryptolepine at bolus doses of 2.5, 5, and 10 micrograms elicited dose-dependent reductions in perfusion pressure b...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199404000-00012

    authors: Oyekan AO

    更新日期:1994-04-01 00:00:00

  • Celiprolol increases coronary blood flow and reduces severity of myocardial ischemia via nitric oxide release.

    abstract::Celiprolol is a selective beta(1)-adrenoceptor antagonist with antihypertensive actions, which causes renal vasodilation by increasing tissue nitric oxide (NO) levels. The authors tested whether celiprolol increases coronary blood flow (CBF) by increasing cardiac NO release in the ischemic heart in vivo. In open-chest...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200304000-00001

    authors: Asanuma H,Node K,Minamino T,Sanada S,Takashima S,Ueda Y,Sakata Y,Asakura M,Kim J,Ogita H,Tada M,Hori M,Kitakaze M

    更新日期:2003-04-01 00:00:00

  • Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.

    abstract:AIMS:To determine whether short-term treatment with trimetazidine (TMZ), an antiischemic agent that directly inhibits fatty acid oxidation and results in stimulation of glucose oxidation, may improve myocardial perfusion and left ventricular systolic function in diabetic patients with ischemic cardiomyopathy. METHODS ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/FJC.0b013e31817bdd66

    authors: Belardinelli R,Cianci G,Gigli M,Mazzanti M,Lacalaprice F

    更新日期:2008-06-01 00:00:00

  • 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.

    abstract::LY53857, spiperone, ketanserin, and setoperone were potent and competitive 5-HT2-receptor antagonists in the rat jugular vein with equivalent affinities at 5-HT2 receptors. In the rat jugular vein, ritanserin blocked 5-HT2-mediated contractile responses with a depression of the maximum response in concentrations great...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Cohen ML,Schenck KW,Kurz KD

    更新日期:1988-01-01 00:00:00

  • Safety and Efficacy of Underdosing Non-vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Catheter Ablation for Atrial Fibrillation.

    abstract:BACKGROUND:Some patients with atrial fibrillation (AF) received underdoses of non-vitamin K antagonist oral anticoagulants (NOACs) in the real world. Underdosing is defined as administration of a dose lower than the manufacturer recommended dose. OBJECTIVES:To identify the efficacy and safety of underdosing NOACs as p...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000448

    authors: Yamaji H,Murakami T,Hina K,Higashiya S,Kawamura H,Murakami M,Kamikawa S,Komatsubara I,Kusachi S

    更新日期:2017-02-01 00:00:00

  • Effects of first and second generation calcium channel blockers on diastolic function of the failing hamster heart: relationship with coronary flow changes.

    abstract::Calcium channel blockers (CCBs) have variable efficacy in the treatment of heart failure. We hypothesized that modulation of left ventricular diastolic pressure (LVDP) may play a role in the variable efficacy of CCBs in this condition. Isolated perfused hearts from 200- to 250-day-old UM-X7.1 cardiomyopathic hamsters ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200307000-00022

    authors: Beaucage P,Massicotte J,Boileau JF,Dumont L

    更新日期:2003-07-01 00:00:00

  • Bergamot essential oil differentially modulates intracellular Ca2+ levels in vascular endothelial and smooth muscle cells: a new finding seen with fura-2.

    abstract::In this study, we compared the effect of the essential oil of Citrus bergamia Risso [bergamot, bergamot essential oil (BEO)] on the intracellular Ca levels in vascular endothelial (EA) and mouse vascular smooth muscle (MOVAS) cells, using the fura-2 fluorescence technique. BEO caused an initial transient increase in i...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0b013e3182834681

    authors: You JH,Kang P,Min SS,Seol GH

    更新日期:2013-04-01 00:00:00

  • Biologics and Cardiovascular Disease.

    abstract::The advent of biologic therapy has enhanced our ability to augment disease in an increasingly targeted manner. The use of biologics in cardiovascular disease (CVD) has steadily increased over the past several decades. Much of the early data on biologics and CVD were derived from their use in rheumatologic populations....

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/FJC.0000000000000595

    authors: Van Taunay JS,Albelda MT,Frias JC,Lipinski MJ

    更新日期:2018-08-01 00:00:00

  • Vasodilator and inotropic effects of the antiarrhythmic drug melperone.

    abstract::We investigated the hemodynamic and inotropic effects of the new class III antiarrhythmic drug melperone. In eight pentobarbital-anesthetized dogs, the effects of intravenous melperone 0.5, 2.5, and 12.5 mg/kg-1 were tested. During atrial pacing we measured cardiac output (CO), mean aortic blood pressure (MAP), right ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198207000-00017

    authors: Platou ES,Smiseth OA,Refsum H,Rouleau JL,Chuck LH

    更新日期:1982-07-01 00:00:00

  • Reversal of left ventricular hypertrophy: a desirable therapeutic goal?

    abstract::It is controversial whether myocardial hypertrophy in essential hypertension represents an adaptive physiologic or pathological response to increased pressure load imposed on the heart. Cardiac structural adaptations in endurance athletes fulfill the criteria of physiologic hypertrophy: maintained cardiac performance ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Schmieder RE,Messerli FH

    更新日期:1990-01-01 00:00:00

  • AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats.

    abstract::The serotonin (5-HT2A) antagonistic activities and the protective effect on laurate-induced peripheral vascular lesions of AT-1015, a novel 5-HT2 receptor antagonist, were investigated. In platelet aggregation, AT-1015 selectively inhibited in vitro 5-HT2A receptor-mediated aggregation, and the activity was almost equ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200004000-00002

    authors: Kihara H,Hirose K,Koganei H,Sasaki N,Yamamoto H,Kimura A,Nishimori T,Shoji M,Yoshimoto R

    更新日期:2000-04-01 00:00:00

  • The effect of cilazapril, a new angiotensin converting enzyme inhibitor, on peak and trough blood pressure measurements in hypertensive patients.

    abstract::Cilazapril (CLZ) is a new, long-acting nonsulfhydril converting enzyme inhibitor (ACE-I). Its effect on peak and trough sitting diastolic blood pressure (SDBP) was studied in a total of 85 patients with uncomplicated, essential hypertension at three centers. After 4 weeks of a single-blind placebo (PLA) run-in period,...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00005344-199101000-00002

    authors: Güntzel P,Kobrin I,Pasquier C,Zimlichman R,Viskoper JR

    更新日期:1991-01-01 00:00:00

  • Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.

    abstract::The pharmacologic profile of SK-1080, a nonpeptide AT1-selective angiotensin-receptor antagonist, was investigated by receptor-binding studies, functional in vitro assays with rabbit and rat aorta, and in vivo experiments in pithed rats. SK-1080 inhibited the specific binding of [125I]-[Sar1, Ile8]-angiotensin II to h...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199903000-00004

    authors: Lee SH,Jung YS,Lee BH,Yun SI,Yoo SE,Shin HS

    更新日期:1999-03-01 00:00:00

  • Simvastatin releases Ca2+ from a thapsigargin-sensitive pool and inhibits InsP3-dependent Ca2+ mobilization in vascular smooth muscle cells.

    abstract::Simvastatin (SV), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity inhibits migration and proliferation of vascular smooth muscle cells (SMC). To investigate whether these effects of SV are related to inhibition of cell calcium mobilization, cultured SMC obtained from rat aorta were l...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199603000-00011

    authors: Escobales N,Castro M,Altieri PI,Sanabria P

    更新日期:1996-03-01 00:00:00

  • The dopamine agonist bromocriptine induces hypotension by venous and arteriolar dilation.

    abstract::Acute bromocriptine administration reduced sitting and standing blood pressure and produced severe orthostatic hypotension in 12 normal subjects. Concomitantly, there was an increase in venous distensibility and basal blood flow, and a decrease in peripheral vascular resistance, as determined by forearm plethysmograph...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198407000-00005

    authors: Johns DW,Ayers CR,Carey RM

    更新日期:1984-07-01 00:00:00

  • Cardiovascular profile of MPC-1304, a novel dihydropyridine calcium antagonist: comparison with other calcium antagonists.

    abstract::The cardiovascular profile of a novel calcium antagonist, MPC-1304 and its active metabolites were investigated in experimental animals in vitro and in vivo, and were compared with those of other calcium antagonists or nitroglycerin (NTG). The ratio of negative chronotropic/negative inotropic effect of MPC-1304 was 23...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199307000-00025

    authors: Kanda A,Haruno A,Miyoshi K,Tanahashi Y,Miyake H,Ichihara K,Okumura K,Nagasaka M

    更新日期:1993-07-01 00:00:00

  • Arginine vasopressin stimulates protein synthesis but not proliferation of cultured vascular endothelial cells.

    abstract::We previously showed that rat and cow blood vessels contain arginine vasopressin (AVP) of local origin. In the present study, to investigate potential roles for this locally produced peptide, we examined the effects of AVP on growth of cultured vascular endothelial and smooth muscle cells (EC, SMC). Treatment of cultu...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199503000-00004

    authors: Simon JS,Baum JS,Moore SA,Kasson BG

    更新日期:1995-03-01 00:00:00

  • Local noradrenaline release in acute myocardial ischemia: influence of catecholamine synthesis inhibition and beta-adrenoceptor blockade on ischemic injury.

    abstract::Left coronary artery ligations or sham operations were performed on pentobarbitone-anesthetized rats. The rats were sacrificed at various times after artery occlusion or sham operation and the creatine kinase (CK), potassium (K+), and noradrenaline (NA) content was determined in the left and right ventricular myocardi...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Abrahamsson T,Almgren O,Svensson L

    更新日期:1981-07-01 00:00:00

  • Cardioprotection from ischemia and reperfusion injury by an endothelin A-receptor antagonist in relation to nitric oxide production.

    abstract::It has previously been shown that endothelin (ET)-receptor antagonists protect the myocardium from ischemia and reperfusion (I/R) injury. The mechanism behind this effect is unclear. The aim of this study was to elucidate the possible interaction between ET(A)-receptor antagonism and nitric oxide (NO) during I/R. Anes...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200009000-00018

    authors: Gonon AT,Gourine AV,Pernow J

    更新日期:2000-09-01 00:00:00